Kymera Therapeutics Inc’s recently made public that its Chief Executive Officer Mainolfi Nello unloaded Company’s shares for reported $2.34 million on Dec 31 ’25. In the deal valued at $78.06 per share,30,000 shares were sold. As a result of this transaction, Mainolfi Nello now holds 663,077 shares worth roughly $48.25 million.
Then, Mainolfi Nello bought 30,000 shares, generating $2,330,700 in total proceeds.
Before that, Esposito Pamela sold 27,563 shares. Kymera Therapeutics Inc shares valued at $2,264,480 were divested by the Director at a price of $82.16 per share. As a result of the transaction, Esposito Pamela now holds 0 shares, worth roughly $0.0.
A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who remained covering the stock and in late October has reiterated a ‘”a Buy”‘ rating for it. Mizuho began covering KYMR with “an Outperform” recommendation on October 21, 2025. H.C. Wainwright maintained its rating on September 18, 2025. It rated KYMR as “a Buy”.
Price Performance Review of KYMR
On Friday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -6.49% to $72.76. Over the last five days, the stock has lost -12.47%. Kymera Therapeutics Inc shares have risen nearly 85.05% since the year began. Nevertheless, the stocks have fallen -6.49% over the past one year. While a 52-week high of $103.00 was reached on 01/02/26, a 52-week low of $19.44 was recorded on 01/02/26.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 70.67, which if violated will result in even more drops to 68.58. On the upside, there is a resistance level at 76.34. A further resistance level may holdings at 79.92.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-12-15, dropping by -0.69 million shares to a total of 7.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 8.58 million shares. There was a decline of -8.7%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 17, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
